Synonym
UTL-5g; UTL 5g; UTL5g;
IUPAC/Chemical Name
N-(2,4-Dichlorophenyl)-5-methyl-3-isoxazolecarboxamide
InChi Key
ULPKSWAQDCJLMN-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H8Cl2N2O2/c1-6-4-10(15-17-6)11(16)14-9-3-2-7(12)5-8(9)13/h2-5H,1H3,(H,14,16)
SMILES Code
O=C(C1=NOC(C)=C1)NC2=CC=C(Cl)C=C2Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
271.09
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Carruthers NJ, Stemmer PM, Chen B, Valeriote F, Gao X, Guatam SC, Shaw J. Phosphoproteome and transcription factor activity profiling identify actions of the anti-inflammatory agent UTL-5g in LPS stimulated RAW 264.7 cells including disrupting actin remodeling and STAT-3 activation. Eur J Pharmacol. 2017 Sep 15;811:66-73. doi: 10.1016/j.ejphar.2017.05.049. Epub 2017 May 31. PubMed PMID: 28576409; PubMed Central PMCID: PMC5581996.
2: Shaw J, Wiegand R, Wu J, Bao X, Valeriote F, Li J. A liquid chromatography with tandem mass spectrometry method for simultaneous determination of UTL-5g and its metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jun 1;991:92-8. doi: 10.1016/j.jchromb.2015.04.015. Epub 2015 Apr 18. PubMed PMID: 25955381.
3: Wu J, Shaw J, Dubaisi S, Valeriote F, Li J. In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent. Drug Metab Dispos. 2014 Dec;42(12):2058-67. doi: 10.1124/dmd.114.060095. Epub 2014 Sep 23. PubMed PMID: 25249693; PubMed Central PMCID: PMC4244871.
4: Swartz K, Zhang Y, Valeriote F, Chen B, Shaw J. Using a simple HPLC approach to identify the enzymatic products of UTL-5g, a small molecule TNF-α inhibitor, from porcine esterase and from rabbit esterase. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Dec 1;940:1-6. doi: 10.1016/j.jchromb.2013.09.021. Epub 2013 Sep 23. PubMed PMID: 24126042; PubMed Central PMCID: PMC3830453.
5: Song Y, Zhang Y, Lee AR, Huang WH, Chen B, Palfey B, Shaw J. Comparison of two molecular scaffolds, 5-methylisoxazole-3-carboxamide and 5-methylisoxazole-4-carboxamide. Curr Pharm Des. 2014;20(1):146-52. Review. PubMed PMID: 23944378.
6: Shaw J, Media J, Chen B, Valeriote F. The small-molecule TNF-α inhibitor, UTL-5g, delays deaths and increases survival rates for mice treated with high doses of cisplatin. Cancer Chemother Pharmacol. 2013 Sep;72(3):703-7. doi: 10.1007/s00280-013-2236-4. Epub 2013 Jul 24. PubMed PMID: 23881213; PubMed Central PMCID: PMC3809999.
7: Shaw J, Chen B, Huang WH, Lee AR, Media J, Valeriote FA. The small-molecule TNF-alpha modulator, UTL-5g, reduces side effects induced by cisplatin and enhances the therapeutic effect of cisplatin in vivo. J Exp Ther Oncol. 2011;9(2):129-37. PubMed PMID: 21699020.